Past Innovation Summits
2012 Innovation Summit - Sustainability through Innovation
Wednesday, October 3, 2012
7:15 a.m. Breakfast/Registration
8:00 a.m. Welcome
8:05 a.m. Michele Brown, Esq., CEO, NJ Economic Development Authority
8:15 a.m. Hans Engel, CEO, BASF Corporation
9:00 a.m. Coffee Break
9:15 a.m. Ian Shankland, VP & CTO, Honeywell Perf. Materials & Technologies
10:00 a.m. Montgomery Alger, VP and CTO, Air Products
10:45 a.m. Networking
Location: Lenfell Hall, Hennessy Hall (Mansion)
Fairleigh Dickinson University's College at Florham
285 Madison Avenue, Madison, NJ 07940
Register here: Eventbrite or at http://innovationfdu.eventbrite.com/
RSVP by September 30th
Hans Engel - Chairman and CEO, BASF
BASF is the world’s leading chemical company: The Chemical Company. Its portfolio ranges from chemicals, plastics, performance products and crop protection products to oil and gas. BASF posted sales of about €73.5 billion in 2011 and had more than 111,000 employees as of the end of the year. BASF Corporation, headquartered in Florham Park, New Jersey, is the North American affiliate of BASF SE, Ludwigshafen, Germany. BASF has more than 16,000 employees in North America, and had sales of $20 billion in 2011.
Hans Engel joined BASF in 1988 in the legal department and has had a variety of roles since. In 1996 he was Staff to the Chairman of the Board of Executive Directors of BASF; in 1997 he was appointed Managing Director of BASF Schwarzheide. Three years later, in 2000, he took the role of Executive Vice President and Chief Financial Officer of BASF Corporation and President Regional Functions North America, Mount Olive, New Jersey. In 2006 he worked on a number of different projects related to the acquisition of Engelhard Corporation and returned to Germany in 2008 as President of Legal, Taxes and Insurance at BASF. That same year (2008) he became Member of the Board of Directors of BASF SE. Since May 6, 2011, Hans Engel is the Chief Financial Officer of BASF SE, Chairman and Chief Executive Officer of BASF Corporation. He is currently responsible for Finance, Catalysts, the Region North America, Information Services & Supply Chain Management, Corporate Controlling and Corporate Audit.
Hans Engel studied law at the Universities of Göttingen and Freiburg in 1983 and earned his Law doctorate degree at the University of Göttingen in 1990.
Monty Alger - Vice President and Chief Technology Officer, Air Products and Chemicals, Inc.
Montgomery (Monty) Alger joined Air Products in February 2007 as vice president and chief technology officer with oversight responsibility for the company’s R&D activities. Prior to joining Air Products, Monty spent 23 years with General Electric, where he most recently was general manager of technology for GE Advanced Materials (silicones and quartz) business, which became Momentive Performance Materials when Apollo Management, L.P. purchased it in late 2006.
Monty joined GE in 1984 at its Corporate Research Center, where he led technology development programs for GE Battery, Lighting, Appliances, and Plastics businesses through 1991. In 1992 he moved to GE Plastics Global Technology and had a number of product and process development roles. In 1998 he became manager of Engineering for GE Superabrasives and in 2000 led the launch of its e-Business website (AbrasivesNet.com). Monty returned to the Global Research Center in 2001 where he was responsible for Advanced Lexan® technology development. He moved to the GE Plastics Noryl® business as manager of Global Technology in 2002 before moving to the GE Advanced Materials business in 2005. He received B.S. and M.S. degrees in chemical engineering from the Massachusetts Institute of Technology in 1978, and a Ph.D. in chemical engineering from the University of Illinois at Urbana-Champaign in 1982. Monty serves on the Chemical Engineering Advisory Councils at the University of Massachusetts-Amherst, Lehigh University, Georgia Institute of Technology and the University of California-Santa Barbara. He also serves on the board of directors of the American Institute of Chemical Engineers and is a member of the National Academy of Engineering. Monty is a certified Six Sigma Master Black Belt.
Ian Shankland - Vice President & Chief Technology Officer, Honeywell Performance Materials & Technologies
Honeywell Performance Materials & Technologies is a global leader in providing customers with high-performance specialty materials, includingfluorocarbons, advanced fibers and composites, specialty additives and films, customized research chemicals, and technology and materials for petrochemical, refining and biofuel industries. Shankland joined Honeywell, then AlliedSignal, 30 years ago and has held a number of positions in research and development and business development, and was named to his current responsibilities in June 2009. At that time, he was Director of Technology for the Fluorine Products business, a leader in the manufacture and supply of non-ozone-depleting refrigerants, blowing agents for energy-efficient foam insulation, hydrofluoric acid, and precursors for nuclear fuel. While with Fluorine Products R&D laboratory in Buffalo New York he led technology programs for successful commercialization of a number of environmentally-improved fluorocarbon products. In 2008, he was awarded the Perkin Medal by the Society of Chemical Industry for these accomplishments. He was also awarded the Western New York Pioneers of Science Award by the Hauptman-Woodward Medical Research Institute in 2011. In his current role Shankland is responsible for R&D, new product development and piloting for Honeywell’s Performance Materials & Technologies business.
Shankland earned his doctorate in physical chemistry from the University of Adelaide in Australia and was awarded a post-doctoral fellowship at Brown University, where he worked for two years with Professor Joseph Kestin prior to joining Honeywell. He is named as an inventor on 62 patents and has published numerous technical and scientific papers.
2010 Innovation Summit - Improving Education and Talent Development
Wednesday, April 14, 2010
The Institute hosted a seminar to help nonprofit as well as for-profit organizations and corporations. New approaches to K–12, higher education and talent development were discussed. Best practices were shared by a variety of experts discussing innovations in the field.
David Grant, President and CEO, Geraldine R. Dodge Foundation. David Grant assumed executive leadership of the Geraldine R. Dodge Foundation in 1998. He is responsible for development and evaluation of programs in the Foundation’s major areas of giving: education, the environment, and the arts in New Jersey, as well as the Foundation’s major initiatives: Poetry, technical assistance to non-profit organizations, and Sustainable Morristown.
David spent his professional career before Dodge as an educator. In 1983 he and his wife, Nancy Boyd Grant, co-founded The Mountain School of Milton Academy, a semester-long, interdisciplinary environmental studies program in Vermont for high school juniors. From 1994 to 1998 David was a national consultant to schools and leader of workshops on topics of curriculum and program design, professional development, assessment practices and school climate.
His public service includes having been Town Moderator of Vershire, Vermont and a Board Member of the Vermont Council for the Humanities. He served as Chair of the Board of the Council of New Jersey Grantmakers from 2006 to 2008 and is currently a member of the Board of Directors of the Surdna Foundation in New York City. David holds an M.A. in American Studies from the University of Michigan and was graduated magna cum laude from Princeton University with an A.B. in English.
Albert J. Browne is the National Program Director and Vice President of Education and Technology for the Verizon Foundation. At Verizon, he is responsible for building the foundation’s initiatives in the Education and Technology space. This includes leading the effort to expand the Foundation’s flagship and signature program –Thinkfinity. The foundation is focused its philanthropic strategy, grant-making and initiatives in the areas of education and literacy, family safety and health, and employee volunteerism. Thinkfinity, the Verizon Foundation’s acclaimed digital platform that provides over 55,000 educational resources to educators is developed in partnership with eleven of the nation’s leading education and literacy organizations.
Albert’s visionary leadership is transforming Thinkfinity to better serve the needs of teachers, community based programs, parents and students in today’s global society by providing advanced and accessible technology, content that infuses 21st century skills into education, and resources that help students, parents and caregivers extend learning beyond the classroom.
Prior to joining Verizon, he was Vice President of Community Preservation and Development Corporation, where he led the startup of three successful divisions, built fifteen Educational Technology Community Centers and raised more than $50 million for education, economic and social programs. Albert serves as a Strategic Council Member for the Partnership for 21st Century Skills organization. He has advanced degrees, certificates in leadership and is an adjunct college and university professor.
Michael B. Horn is the co-founder and Executive Director of Education of Innosight Institute, a not-for-profit think tank devoted to applying the theories of disruptive innovation to problems in the social sector. He is the coauthor of Disrupting Class: How Disruptive Innovation Will Change the Way the World Learns (McGraw-Hill: with Harvard Business School Professor and bestselling author Clayton M. Christensen and Curtis W. Johnson, president of the Citistates Group. BusinessWeek named the book one of the 10 Best Innovation & Design Books of 2008, Strategy + Business awarded it the best human capital book of 2008, Newsweek named it as the 14th book on its list of “Fifty Books for Our Times,” and the National Chamber Foundation named it first among its 10 “Books that Drive the Debate 2009.”
Disrupting Class uses the theories of disruptive innovation to identify the root causes of schools’ struggles and suggests a path forward to customize an education for every child in the way he or she learns. Horn has been a featured keynote speaker at many conferences including the Virtual School Symposium and Microsoft’s School of the Future World Summit.
Horn has written articles for numerous publications, including Education Week, Forbes, the Boston Globe, and U.S. News & World Report. Horn earned his MBA from Harvard Business School and an AB from Yale University, where he graduated with distinction in History.
Judy Zagorski, Head of HR, Development & Strategy, BASF
Judy A. Zagorski has a B.A., cum laude, in Psychology and English Literature from Gettysburg College. During her professional career, she was nominated to attend Mars, Incorporated’s President’s Global Leadership Program (faculty from London Business School, Duke University, Harvard Business School and Center for Creative Leadership). She is a member of the Human Resources Planning Society, SHRM and the OD Network and has presented frequently at The Conference Board.
Judy joined BASF Corporation in 2007 as Vice President, Human Resources, Development and Strategy. Previously, she spent over 15 years with Mars, Incorporated where she was the global Chief Talent Officer and, most recently, Vice President, Human Resources for Mars Snackfoods.
Her previous professional experience includes roles as Global Human Resources Director for Honeywell’s Engineered Plastics business division and management consulting positions with KPMG and Human Resource Management, Inc.
Vas Nair, former Chief Learning Officer, Schering-Plough
Vas was formerly Vice President & Chief Learning Officer at Schering Plough Corporation with over 15 years global HR experience. She started her career in Sydney, Australia and moved into roles with increasing scope at companies such as ANZ Bank, Prudential, Pharmacia and Schering Plough Corporation. In her global capacity at Schering Plough, she successfully established a learning and talent management infrastructure that supported the company’s vision, values and people strategy.
Due to her passion for professional development, she was elected Schering Plough's first Women's Network Steering Committee chairperson.Vas is a board member of the American Red Cross, Colonial Crossroads chapter, NJ; and serves as an advisor to the Susan G. Koman North Jersey board.
She is the recipient of the 2005 YWCA Tribute To Women In Industry (TWIN) award and is a VIP member of Cambridge’s Who’s Who Executive and Professional Registry. Vas holds an MBA in strategic human resource management from the University of New England, Australia, and a Bachelor of Commerce degree from Wollongong University Australia.
Jason Scorza, Associate Provost, Global Learning, FDU
Jason Scorza is Associate Provost for Global Learning and Professor of Political Science and Philosophy at Fairleigh Dickinson University.
Scorza is a major contributor to Fairleigh Dickinson's global education and distance learning initiatives and is co-recipient of the Instructional Technology Council (ITC) award for Outstanding Online Course and recipient of the Sloan Consortium Award for Excellence in Online Teaching. Under his leadership, Fairleigh Dickinson University was recognized with a 2009 Spotlight Award by NAFSA: Association of International Educators for its exceptional use of technology to promote campus internationalization. In 2007, Scorza was chosen to participate in the prestigious American Council on Education (ACE) Fellows Program.
Scorza earned his Ph.D. in Politics at Princeton University and is author of a book, Strong Liberalism: Habits of Mind for Democratic Citizenship (Tufts University Press, 2007), as well as articles appearing in journals including Political Theory, The Review of Politics, Theory and Research in Education, Asynchronous Learning Networks, and the International Journal of Politics and Ethics.
2009 Innovation Summit.collaboration
This intensive seminar was held on Tuesday, April 28. It was designed to help the executive management teams of small and medium-sized businesses and large corporations better understand how to implement innovation and effectively collaborate inside and outside their organizations. The morning featured presentations from innovation leaders.
Presentated in collaboration with the NJ Technology Council.
Deborah L. Wince-Smith, President, Council on Competitiveness
Deborah Wince-Smith is the president of the Council on Competitiveness - a premiere group of CEOs, university presidents and labor leaders committed to driving U.S. competitiveness. Since her appointment as President in 2001, she has spearheaded a national campaign that made innovation a top-tier national policy issue. Smith is recognized in the global business community as a “go to” person for strategic counsel, as exemplified by her appointment to the Board of Directors of the NASDAQ OMX Group, Inc. and the NASDAQ Stock Exchange.
As president of the Council, Smith’s expertise in technology policy, economic development and global competition is frequently sought after by government, industry and news media.She is a member of the Oversight Board of the IRS and of the U.S. Dept of State’s Advisory Committee on International Economic Policy.
Her eclectic knowledge and prescient foresight have been called on by three presidents. She has more than 20 years of experience as a senior U.S. government official. Following her government tenure, Wince-Smith became active in governance of various national scientific laboratories and provided strategic counsel to several FORTUNE 100 companies. Since becoming president of the Council, Smith has helped recharge the national debate on competitiveness, innovation and resilience.
Carlos Dominguez, Senior Vice President, Cisco
Carlos Dominguez is a Senior Vice President in Cisco’s Office of the Chairman of the Board and CEO. He advocates for the broad and creative use of technologies that are transforming how companies do business and creating distinct competitive advantages and new business models for those who adopt them. Dominguez says video, Web 2.0 applications and the increasing use of social networks, at home and at work, are at the heart of the collaboration revolution that is helping companies use the power of collective intelligence to produce revolutionary ideas for new products, better customer service and greater cost reductions.
Dominguez has been with Cisco for 17 years and has first-hand experience in how Cisco deploys technology in good, and bad, economic times to drive productivity and growth. Dominguez also advises Cisco customers about technology strategy and direction. He spends times with startup companies operating solely on the web as well as with established companies that are interested in using Internet innovations to do business differently.
He spent most of his career at Cisco with service providers, including cable operators, mobile operators and content providers. He sits on Cisco’s Mexico Board and the Cisco Foundation Board.
Andrew Bushell, Executive Director, Cardiovascular and Metabolism Franchise, Novartis Pharmaceuticals
Andy Bushell is the Global Portfolio Team Leader for Diovan, Exforge and Lotrel at Novartis Pharmaceuticals. In his position he has responsibility for delivering global development activities for these world-leading medicines through the collaboration of colleagues in every country of the world.
Prior to his current role he was Head of Innovation and Global R&D Operations at Novartis Consumer Health where he explored the link between collaboration and the culture of innovation in order to provide innovative new products to consumers world-wide. Before joining Novartis Bushell was Head of Full Development Project Management for Pfizer, where he successfully experimented with non-hierarchical departmental structure to better facilitate collaboration and personal development of his group.
He has over 20 years experience in discovering, developing and commercializing medicines world-wide, having held positions of increasing responsibility in Research, Sales and Marketing, Clinical Development, Team Leadership, Project Management and Innovation, with companies including Beecham, Glaxo, Astra, Zeneca, Pfizer and Novartis.
Jason Fried, Co-founder and President, 37signals
Jason Fried is the co-founder and President of 37signals, a privately-held Chicago-based company committed to building the best web-based ... tools possible with the least number of features necessary. 37signals' products include Basecamp, Highrise, Backpack, Campfire, Ta-da List, and Writeboard. 37signals also developed and open-sourced the Ruby on Rails programming framework. 37signals' products do less than the competition - intentionally. Jason believes there's real value and beauty in the basics. Elegance, respect for people's desire to simply get stuff done, and honest ease of use are the hallmarks of 37signals products.
2008 Innovation Summit featuring Innovation Leaders from BD, Merck and Celgene Corporation
Wednesday, April 30, 2008
Ed Ludwig, Chairman, President and CEO, BD
Mervyn Turner, SVP, Worldwide Licensing & External Research, Merck
Robert Hugin, Pres
Panel - Innovation Insights from Biotech Entrepreneurs/Leaders
Moderator: Joseph Healy, Chairman, Kolmar Labs Group
Arthur Alfaro, Founder and CEO, ORTHOCON
Vivian Liu, Co-founder and CEO, NexMed
Elizabeth Posillico, President and CEO, Elusys Therapeutics, Inc.
Glenn Sblendorio, EVP and CFO, The Medicines Company
Edward J. Ludwig serves as Chairman of the Board, President and Chief Executive Officer of BD (Becton, Dickinson and Company), a global medical technology company headquartered in Franklin Lakes, New Jersey. BD, which manufactures and sells medical devices, instrument systems and reagents, is dedicated to improving people’s health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases and advancing research and discovery of new drugs and vaccines. The Company’s capabilities are instrumental in combating many of the world’s most pressing diseases.
Mr. Ludwig joined BD in 1979. His previous roles have included President, Becton Dickinson Diagnostic Systems; Vice President, Planning and Development; Senior Vice President and Chief Financial Officer. Named President in May 1999 and Chief Executive Officer in January 2000, Mr. Ludwig was elected Chairman in February 2002.
Prior to joining BD, Mr. Ludwig served as a senior auditor with Coopers and Lybrand (now Pricewaterhouse Coopers) and as a financial and strategic analyst at Kidde, Inc. Mr. Ludwig graduated from The College of the Holy Cross with a B.A. in Economics and Accounting and received his M.B.A. in Finance from Columbia University. He is also a C.P.A.
Dr. Mervyn Turner joined Merck Research Laboratories in 1985. Over the last 22 years, he has held many positions of increasing responsibility at Merck. In August 1999, Dr. Turner was appointed Senior Vice President, Merck Frosst Centre for Therapeutic Research in Montreal, Canada. Dr. Turner returned from his assignment in Montreal in October 2002 to take up his current position as Senior Vice President, Worldwide Licensing and External Research. In this role, he is responsible for the oversight of all of Merck’s licensing activities and for the management of academic relations. Through his multiple and diverse experiences in the Merck Research Laboratories, Dr. Turner has acquired a broad perspective on the issues surrounding drug discovery and development.
2004 through 2007 saw a sizeable increase in deal activity for Merck, with over 190 transactions completed. Merck has also been active in M&A, with Aton, Abmaxis, GlycoFi, Sirna and NovaCardia, all acquired to build areas of key strategic importance. Dr. Turner sees all this activity as a logical product of a cultural shift within Merck towards a more outward-facing organization.
Dr. Turner is the author of over 80 articles in peer reviewed journals. He has served on the Editorial Board of a number of journals, and since 1998 has been a member of Health Care Ventures Scientific Advisory Board.
Robert J. Hugin serves as President and Chief Operating Officer of Celgene Corporation, a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for unmet medical needs in cancer and immune-inflammatory disease. He joined Celgene in June 1999 and has been a Director of Celgene since December 2001. Mr. Hugin also serves as a Director of The Medicines Company, Atlantic Health System, Inc. and of Family Promise, a national non-profit network assisting homeless families. Prior to joining Celgene, Mr. Hugin was a Managing Director with J.P. Morgan & Co. Inc. Mr. Hugin received an AB degree from Princeton University in 1976 and an MBA from the University of Virginia in 1985 and served as a United States Marine Corps infantry officer during the intervening period.
Bob and his wife, Kathy, live in Summit, New Jersey, with their three children.
PROFILES of PANEL
Arthur A. Alfaro is Founder, President, and Chief Executive Officer of Orthocon, a specialty pharmaceutical and medical device company focused in the treatment of postoperative pain using a novel intraoperative, absorbable technology. Prior to Orthocon he founded Orthotherapeutics, a biomaterials company and had been President, Chief Operating Officer, and Board Member of Osteotech, a publicly traded company in the allograft tissue and spinal fusion market. Earlier, Mr. Alfaro was President at Sofamor Danek Company, which was acquired by Medtronic during his tenure. Mr. Alfaro’s previous experience also includes serving as General Manager at Boston Scientific Corporation. He began his career in the healthcare industry with Ethicon, a Johnson & Johnson Company. Mr. Alfaro holds a BS from the University of Maryland and an MBA from Fairleigh Dickinson University.
Joseph M. Healy is Chairman of the Board of Kolmar Labs Group, Woodcliff Lake, NJ. Mr. Healy initially joined Outsourcing Services Group, the then parent company of Kolmar Labs Group, as its Chief Executive Officer in July 2000 and served in that capacity until April 2004. Prior to joining the Company, Mr. Healy was the President and Chief Executive Officer of Reckitt & Colman, Inc., a global manufacturer and marketer of household/food and personal care products. Prior thereto, Mr. Healy was President of the L&F Household Products Division. Earlier in his career, Mr. Healy held key managerial positions in sales, marketing and new product development at L&F Products. Mr. Healy serves on several civic and industry boards, including United Way of Bergen County, the Personal Care Products Council and is President of the Alliance for Consumer Education in Washington, DC and a Board Member of . Mr. Healy holds a B.A. degree in finance and economics from Fairleigh Dickinson University. He resides in Ho-Ho-Kus, NJ with his wife Jeanne and is the proud father of four and grandfather of five.
Vivian Liu was named President and Chief Executive Officer of NexMed and was elected to the Board of Directors in June 2007 after having served in various capacities, including Executive Vice President and Chief Operating Officer, interim CEO, as well as Chief Financial Officer and Vice President of Corporate Affairs. Prior to joining NexMed thirteen years ago, Ms. Liu was the Commercial Attaché with the Delegation of Quebec in Los Angeles, responsible for business development projects for the medical, pharmaceutical and biotechnology industries. Ms. Liu has an M.P.A. from the University of Southern California and a B.A. from University of California, Berkeley.
Elizabeth G. Posillico serves as President & CEO of Elusys Therapeutics, Inc. She has 20 years of experience in the biopharmaceutical industry and has held senior positions in general management, business development, marketing and operations. She joined Elusys in 2002 as Vice President of Business Development and since then was promoted to Sr.Vice President of Operations and then President and CEO in January, 2005. Prior to joining Elusys, Elizabeth was Vice President of Business Development and Marketing at Physiome Sciences, and Sr. Vice President of Business Development at Apoptogen, Inc. She also served on the management committee of the Canadian Medical Discovery Fund, an early-stage venture capital fund. Elizabeth spent eight years at Genzyme Corporation in several executive positions.
Elizabeth serves on the New Jersey Governor's Economic Growth Council and is a member of the Board of Directors of BioNJ, and the Girl Scouts of Northern New Jersey. Elizabeth received a BA degree from the State University of New York at Potsdam and a PhD from Duke University.
Glenn P. Sblendorio has been our Chief Financial Officer and Executive Vice President since March 2006. Prior to joining The Medicines Company, Mr. Sblendorio was Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. until it was acquired by OSI Pharmaceuticals, Inc. in November 2005. From July 2000 to February 2002, Mr. Sblendorio served as Senior Vice President of Business Development for The Medicines Company. From 1998 to July 2000, Mr. Sblendorio was the Chief Executive Officer and Managing Director of MPM Capital Advisors, LLC, an investment bank specializing in healthcare related transactions. Mr. Sblendorio's pharmaceutical experience also includes 12 years at Hoffmann-LaRoche, Inc., a pharmaceutical company, in a variety of senior financial positions, including Chief Financial Officer of Roche Molecular Systems and Head of Finance-Controller for Amgen/Roche Europe. Mr. Sblendorio received his B.B.A. in accounting from Pace University and his M.B.A. in Finance from Fairleigh Dickinson University.
2007 Innovation Summit
featuring Innovation Leaders from Johnson & Johnson, Cadbury Schweppes and Gain Capital.
Wednesday, April 18, 2007
Tom Reynolds, Vice President of Worldwide Marketing for Johnson & Johnson Wound Management, is responsible for all aspects of marketing and product development. With over 15 years of executive experience in building business through creative innovation in the consumer, medical device, pharmaceutical, diagnostic and financial fields. Reynolds has a record of success with emerging and established technologies within both rapidly expanding and mature markets. He has developed several unique programs integrating tools from a number of academic disciplines with various industrial practices to create and enhance products, build effective teams, and accelerate flows in new-product pipelines. Reynolds most recently spearheaded an initiative on Customer Focused Innovation, focused on implementing new product development approaches within the company.
Jose Amarista, Director, Latin America Product Development, Cadbury Schweppes, is responsible for driving growth in the region for gum and confectionery products through innovation and value optimization, covering all aspects of product/process development. He manages the development labs in Mexico, Brazil and Colombia as well as a group in the US to provide technical support worldwide. Previously, Amarista worked as Director of Product Development for Latin America, Senior Manager in Gum Base Development and Youth and Fun Products. Prior to Cadbury Schweppes, he worked in Product and Process Development at Procter & Gamble for Bar Soaps for Latin America (Zest, Camay and Safeguard). Cadbury Schweppes is the world’s leading confectionery company and 3rd largest soft drinks company. Innovation initiatives and emerging markets have helped yield revenue growth of over 10%.
Mark Galant is Chief Executive Officer of GAIN Capital Group, one of the first independent firms in the U.S. to offer online currency trading services. One of the innovators in this industry, the firm runs the well known FOREX.com brand for individual investors and also services hedge funds and professional money managers. Founded in 1999 by Galant, GAIN has grown from a start up into a global firm with more than 200 employees supporting clients in more than 140 countries. It has earned many accolades including Inc. 500 listings in 2005 and 2006. Prior to forming GAIN Capital in 1999, Galant was the number two executive at FNX Limited, a global provider of trading and risk management systems. Before FNX, he served as global head of foreign exchange options trading at Credit Suisse. There, he expanded it into one of the world's largest global foreign exchange options trading organizations, trading $4 billion per day.
Wednesday, April 5, 2006
2006 Innovation Summit featuring Clayton Christensen
• Creating Opportunities Out of Disruptive Innovation
• Making the Process of Innovation Predictable and Repeatable
• Deploying the Right Kind of Strategy at the Right Time
• Developing a New Business Model to Create a Growth Engine
• Shaping an Organization Structure Capable Of Disruptive Growth
This seminar is designed to help the executive management teams of medium-sized businesses, large corporations and nonprofits better understand how to implement innovation at their organizations. The morning session will include a presentation by the world-renowned, innovation author and consultant, Clayton Christensen. An interactive lunch panel consisting of innovation leaders will then share ideas on achieving profitable growth through innovation.
Lunch PanelDavid Attis, Director, Policy Studies, Council on Competitiveness
Leonard C. Green, CEO, The Green Group
Andrew Kaldor, Lab Director for Corporate Strategic Research, ExxonMobil Research and Engineering Company
Ken Massey, Vice President, Field Operations, U.S. CD&MA, Novartis Pharmaceuticals
Cecil B. Pickett, Senior Vice President, Schering-Plough Corporation, and President, Schering-Plough Research Institute
Clayton M. Christensen, world renowned for his work on innovation and disruption, is the Robert and Jane Cizik Professor of Business Administration at the Harvard Business School. He is one of the most sought-after business consultants in the innovation area and is an adviser to some of America’s most successful companies. His research and teaching interests center on the management issues related to the development and commercialization of technological and business model innovation. Specific areas of focus include developing organizational capabilities and finding new markets for new technologies. Professor Christensen is the author of the bestselling books: The Innovator’s Dilemma (1997), which received the Global Business Book Award for the best business book published in 1997, and The Innovator’s Solution (2003), which appeared in the BusinessWeek bestseller list. His most recent book, Seeing What’s Next, was published in 2004. In addition, he edited two casebooks on innovation: Innovation and the General Manager (1999) and Strategic Management of Technology and Innovation, 4th edition (2004) and has published award winning articles in the Harvard Business Review.
Leonard Green has had a long and distinguished career as an entrepreneur and as a nationally known tax expert and family business consultant. Len is President and Founder of The Green Group, a tax and financial services consulting firm in Woodbridge, NJ. Len currently teaches an Entrepreneurial Management course at FDU. He has also taught courses structured like the “Apprentice” television series as well as entrepreneurial family business at Babson College. His classes have been featured on CNBC Squawk Box and ABC TV. Articles about Len have appeared in over 200 newspapers including the Wall Street Journal and Star Ledger. Most recently, Len was featured in the January 2006 INC Magazine article, “How To Properly Value A Business”. Len received his MBA from Harvard Business School’s Owner and President Management Program. He received his Masters Degree in Taxation (Honors) from New York University and his undergraduate degree from Rutgers University (Accounting). Len is on the advisory board of many family-owned businesses and consults to over 1,000 clients. He is on the board of directors of NYSE-listed Cenveo, Inc. and three non-profits. He is an owner or investor in many diverse businesses.
Cecil B. Pickett, Ph.D., is senior vice president of Schering-Plough and president, Schering-Plough Research Institute (SPRI), the pharmaceutical research arm of Schering-Plough Corporation. Appointed to his present position in March 2002, Dr. Pickett is responsible for all aspects of SPRI. He joined Schering-Plough Research Institute in 1993, as executive vice president, discovery research, responsible for the planning, management and oversight of Schering-Plough’s new drug discovery programs across all therapeutic areas. Dr. Pickett has a track record of applying creativity – and innovative solutions – to new drug discovery. Dr. Pickett came to SPRI from Merck Research Laboratories, where he served as senior vice president, basic research. During his 15-year employ at Merck & Co., Dr. Pickett held various positions of increasing responsibility. He received a B.S. degree in biology from California State University, and his Ph.D. degree in cell biology from the University of California, Los Angeles (UCLA). Dr. Pickett has been published extensively in leading research journals and has been a frequent speaker at scientific symposia and conferences. He has received several major academic awards, appointments and fellowships, and serves on a number of scientific committees and editorial boards of medical journals and research organizations.
Andrew Kaldor received his B.S. in Chemistry at the University of California, Berkeley and his Ph.D. in Physical Chemistry at Cornell University. He worked at the National Bureau of Standards in Gaithersburg, MD before joining Exxon in 1974. He worked in Corporate Research in a variety of assignments and has been the director of a number of its Laboratories. From 1993-1999 he was the Director of the Fuels Process Development Laboratory in Baton Rouge. He currently works in Clinton, NJ at ExxonMobil Research & Engineering Company where he is the Manager of Lead Generation and Breakthrough Research. Dr. Kaldor has published over 100 technical papers in surface chemistry, chemical kinetics, laser chemistry and spectroscopy, laser physics, laser isotope separation, and catalysis, as well as holds over twenty patents. He received the Silver Medal from the Department of Commerce, as well as other honors. He has presented invited and plenary lectures at numerous international conferences. He has served on numerous advisory committees to Universities, National Laboratories, and to Government Agencies. He is a past chair of the trustees of the Gordon Research Conferences.
Dr. Kenneth L. Massey is currently Vice President, US Clinical Development and Medical Affairs at Novartis Pharmaceuticals Corporation where he is responsible for all aspects of the organization’s field based medical and clinical operations teams. Ken has more than 18 years of pharmaceutical industry experience, 15 of which have been focused in the development and management of regional medical programs.Prior to joining the pharmaceutical industry, Ken held faculty appointments at the University of Tennessee Colleges of Pharmacy and Medicine in Memphis. Dr. Massey focused his educational and original research efforts in the management of pediatric patients, and directed a pharmacology consultation service at LeBonheur Children’s Hospital. Ken received his Bachelor of Science and Doctor of Pharmacy degrees from the University of Florida in Gainesville and completed a two-year post-doctoral fellowship in pediatric clinical pharmacology.
David Attis serves as the Deputy Director of the National Innovation Initiative, a multi-year effort to increase America’s capacity for innovation. Led by a Leadership Council of CEOs, university presidents and labor leaders, the initiative released its major report, Innovate America, in December of 2004. David also served as a policy consultant on the National Academies’ Rising Above the Gathering Storm report in 2005. Both reports led to bipartisan legislative proposals and contributed to the President’s American Competitiveness Initiative. David also directs all of the research for the Council’s flagship publication, the Competitiveness Index, chaired by Professor Michael Porter of Harvard Business School. Prior to joining the Council, David was a consultant with A.T. Kearney, Inc. both in their general consulting practice and in their Global Business Policy Council. His work included business turnarounds, strategy consulting, information systems implementation, global risk assessments and policy analysis. David holds a PhD in the History of Science from Princeton University and BA in Physics from the University of Chicago. His doctoral thesis explored the history of mathematics in Ireland from the surveyors of the seventeenth century through the Celtic Tiger economy of the 1990s.